Key Insights

Highlights

Success Rate

80% trial completion

Published Results

19 trials with published results (19%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 39/100

Termination Rate

8.8%

9 terminated out of 102 trials

Success Rate

79.5%

-7.0% vs benchmark

Late-Stage Pipeline

12%

12 trials in Phase 3/4

Results Transparency

54%

19 of 35 completed with results

Key Signals

19 with results80% success

Data Visualizations

Phase Distribution

71Total
Not Applicable (10)
Early P 1 (3)
P 1 (17)
P 2 (29)
P 3 (11)
P 4 (1)

Trial Status

Completed35
Recruiting22
Unknown17
Terminated9
Withdrawn8
Active Not Recruiting7

Trial Success Rate

79.5%

Benchmark: 86.5%

Based on 35 completed trials

Clinical Trials (102)

Showing 20 of 20 trials
NCT07387549Phase 3RecruitingPrimary

A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis

NCT05642468Phase 2TerminatedPrimary

Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis

NCT05627362Phase 2Active Not RecruitingPrimary

A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.

NCT06286709Phase 2RecruitingPrimary

FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitis

NCT04685200RecruitingPrimary

Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach

NCT03710122Phase 2TerminatedPrimary

Vancomycin for Primary Sclerosing Cholangitis

NCT06519162Recruiting

Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome

NCT05896137Phase 2Active Not RecruitingPrimary

CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)

NCT03561584Phase 2CompletedPrimary

Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis

NCT04678219Not ApplicableCompletedPrimary

A Pilot Study Examining Diet in Primary Sclerosing Cholangitis

NCT07229911Phase 1Recruiting

A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)

NCT05912387Early Phase 1RecruitingPrimary

Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study

NCT03445585RecruitingPrimary

Biobank for Cholestatic Liver Diseases.

NCT04753996RecruitingPrimary

Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients

NCT04663308Phase 2Active Not RecruitingPrimary

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

NCT04480840Phase 2CompletedPrimary

Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)

NCT06026449Not ApplicableActive Not RecruitingPrimary

Gluten-free Diet in PSC and IBD

NCT03743272Completed

Repeatability and Reproducibility of Multiparametric MRI

NCT06455280Phase 1Recruiting

A Study of SIPLIZUMAB in AILD and LT Patients

NCT05835505Phase 2RecruitingPrimary

Detoxification of the Liver In PSC (Dolphin)

Scroll to load more

Research Network

Activity Timeline